TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in Nature identifies claudin-4 as the protein that lets B. fragilis toxin attach to colon cells before damaging them. Researchers also report that a molecular decoy protected mice from the toxin, but the findings do not show that the approach prevents cancer in people.
Researchers led by Johns Hopkins scientists have identified claudin-4 as the protein that allows a toxin made by some strains of the gut bacterium Bacteroides fragilis to attach to colon cells. The study, published in Nature, also reports that a molecular decoy protected mice from the toxin’s effects, pointing to a possible way to block bacterial damage linked to colorectal cancer—but not yet a proven cancer-prevention treatment.
The toxin, called B. fragilis toxin (BFT), was already known to damage the colon’s protective lining and contribute to inflammation and tumor growth in research. The missing piece was how it first reached its target. Earlier work showed that BFT damages E-cadherin, a protein that helps neighboring cells stay connected, but the toxin did not appear to bind directly to E-cadherin.
To find the initial point of contact, the researchers used a genome-wide CRISPR screen to switch off genes in colon-lining cells and test which changes stopped toxin binding. The gene for claudin-4 emerged as the strongest result. When that gene was disabled, BFT could no longer attach to the cells or attack E-cadherin, the team reported. Laboratory experiments with structural biology collaborators also found that BFT and claudin-4 form a tightly bound complex.
The team then developed a molecular decoy intended to intercept the toxin before it could bind to cells. The decoy protected mice from harmful effects of BFT in the reported experiments. The source does not describe this as a human trial or establish that the approach prevents colorectal cancer in people.
Blocking the Toxin Before Cell Damage
Identifying the first step in BFT’s attack gives researchers a specific target for studying how certain gut bacteria can contribute to damage associated with colorectal cancer. If a way to block the interaction can be made safe and effective, it could offer a route to limiting the toxin’s effects before it disrupts the colon barrier. The mouse result is an early proof of concept, not evidence that people can currently use a decoy to lower cancer risk.
The finding may also matter beyond cancer research. Senior author Cynthia Sears said that understanding how bacterial toxins work could inform approaches to diseases associated with them, including diarrhea and bloodstream infections. Those potential applications remain research goals; the reported study establishes a receptor mechanism and a result in mice, not a treatment for these conditions.
Products Worth Considering
Fitbit Sense 2 Health and Fitness Smartwatch (Lunar White/Platinum)
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
Blueair Blue Pure 511i Max Smart Air Purifier
As an affiliate, we earn on qualifying purchases.
From Bacterial Toxin to Receptor
B. fragilis can live in the intestines of as many as 20% of healthy people, according to the source material. Its presence alone does not mean a person will develop cancer. The concern is that some strains produce BFT, which can disrupt the colon’s protective lining, provoke inflammation and encourage tumor growth.
In a 2009 study in Nature Medicine, Sears and colleagues reported that BFT could promote colon tumor development. Later work linked the toxin to breakdown of E-cadherin, but left open how BFT reached that protein. The new study fills in that step by identifying claudin-4, which helps neighboring cells form tight junctions that regulate movement between them.
The result was unexpected, the researchers said, because they had looked for a receptor involved in cell signaling. Claudin-4 instead plays a structural role in cell junctions. The team described BFT’s need to bind a separate receptor before acting on its protein target as an unusual mechanism for a toxin that cuts proteins.
““We’ve made several attempts over time to identify the receptor, so this is an exciting moment.””
— Cynthia Sears, senior author and professor at Johns Hopkins
Human Benefits Remain Unproven
The study’s reported protective result came from experiments in mice. The available source material does not specify whether the decoy has been tested in people, whether it can be delivered safely to the human colon, or whether it can prevent tumors over time. It also does not provide details on a clinical development plan or a timeline for human studies.
Researchers have identified a mechanism for BFT, but that does not mean every B. fragilis strain produces the toxin or that carrying a toxin-producing strain inevitably leads to cancer. How often this mechanism contributes to human colorectal cancer, and which people might benefit from a future intervention, remain unresolved.
Testing the Decoy Beyond Mice
The immediate next steps are not specified in the source report. Further research would need to test whether the decoy can reliably block BFT in more settings, establish how it affects the colon and other tissues, and assess safety before any human use could be considered. Researchers would also need to determine whether blocking the toxin changes cancer outcomes, rather than only preventing short-term toxin damage in experimental models.
The work was partially supported by the National Institutes of Health. For now, the main confirmed development is the identification of claudin-4 as BFT’s docking point and a promising result in mice, not a new screening recommendation or available therapy.
Key Questions
What did the researchers discover?
They identified claudin-4 as the protein B. fragilis toxin binds to before it damages colon cells.
Does having B. fragilis mean someone will get colon cancer?
No. The source says the bacterium can be found in the intestines of up to 20% of healthy people, and its presence alone does not mean someone will develop cancer. Some strains produce the toxin studied.
Has the molecular decoy been shown to prevent cancer in people?
No human benefit is established in the report. The researchers say the decoy protected mice from the toxin’s harmful effects; whether it can prevent cancer or be used safely in people remains unknown.
How does BFT damage colon cells?
According to the study, BFT first binds to claudin-4 and then attacks E-cadherin, a protein that helps keep neighboring cells connected. Damage to E-cadherin can weaken the colon’s protective lining.
Source: sciencedaily.com
